On July 1 Pfizer Inc. announced it was discontinuing development of Phase III COPD drug roflumilast (Daxas) and of Phase IIb HIV/AIDS drug capravirine, due to disappointing clinical results. Roflumilast was returned to co-development partner and originator Altana AG , and ex-Asian rights to capravirine reverted to Shionogi & Co. Ltd. [See Deal][See Deal]
Pfizer says the decisions are part of its regular and routine review of pipeline opportunities. But they come just three...





